Hu5F9-G4 (magrolimab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Hu5F9-G4 (magrolimab), covering 2024-05-02 to 2024-05-02. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations [Phase 1]